Name | Number of supported studies | Average coverage | |
---|---|---|---|
fibroblast | 33 studies | 25% ± 8% | |
mast cell | 25 studies | 34% ± 13% | |
macrophage | 18 studies | 24% ± 6% | |
pericyte | 16 studies | 26% ± 10% | |
monocyte | 10 studies | 25% ± 8% | |
connective tissue cell | 10 studies | 23% ± 8% | |
smooth muscle cell | 10 studies | 20% ± 6% | |
non-classical monocyte | 9 studies | 29% ± 15% | |
natural killer cell | 8 studies | 19% ± 2% | |
conventional dendritic cell | 8 studies | 23% ± 5% | |
epithelial cell | 8 studies | 33% ± 15% | |
astrocyte | 6 studies | 34% ± 15% | |
myeloid cell | 6 studies | 22% ± 5% | |
basal cell | 6 studies | 19% ± 3% | |
cardiac muscle cell | 6 studies | 48% ± 17% | |
enterocyte | 5 studies | 27% ± 7% | |
endothelial cell | 5 studies | 20% ± 3% | |
ciliated cell | 5 studies | 28% ± 12% | |
oligodendrocyte precursor cell | 4 studies | 23% ± 6% | |
CD16-positive, CD56-dim natural killer cell, human | 4 studies | 19% ± 2% | |
classical monocyte | 4 studies | 29% ± 7% | |
retinal bipolar neuron | 4 studies | 22% ± 5% | |
retina horizontal cell | 4 studies | 40% ± 10% | |
adventitial cell | 4 studies | 24% ± 4% | |
type II pneumocyte | 4 studies | 17% ± 2% | |
dendritic cell | 4 studies | 33% ± 15% | |
pancreatic A cell | 3 studies | 46% ± 11% | |
GABAergic neuron | 3 studies | 30% ± 9% | |
hematopoietic precursor cell | 3 studies | 43% ± 15% | |
extravillous trophoblast | 3 studies | 34% ± 14% | |
myofibroblast cell | 3 studies | 25% ± 10% | |
club cell | 3 studies | 32% ± 13% | |
Mueller cell | 3 studies | 22% ± 3% | |
rod bipolar cell | 3 studies | 58% ± 5% | |
secretory cell | 3 studies | 19% ± 2% | |
abnormal cell | 3 studies | 24% ± 1% | |
enteroendocrine cell | 3 studies | 31% ± 8% | |
alveolar macrophage | 3 studies | 24% ± 9% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
breast | 99% | 2100.21 | 456 / 459 | 98% | 22.71 | 1098 / 1118 |
adrenal gland | 100% | 1993.39 | 258 / 258 | 97% | 60.99 | 224 / 230 |
stomach | 100% | 2267.04 | 359 / 359 | 96% | 24.65 | 275 / 286 |
intestine | 100% | 2219.61 | 965 / 966 | 96% | 19.89 | 507 / 527 |
lung | 100% | 2345.21 | 577 / 578 | 96% | 25.50 | 1106 / 1155 |
uterus | 99% | 2671.01 | 169 / 170 | 96% | 20.96 | 440 / 459 |
thymus | 100% | 2392.32 | 652 / 653 | 95% | 21.86 | 575 / 605 |
prostate | 100% | 2121.22 | 245 / 245 | 94% | 13.65 | 472 / 502 |
esophagus | 95% | 1102.72 | 1378 / 1445 | 98% | 30.82 | 180 / 183 |
bladder | 100% | 2832.00 | 21 / 21 | 93% | 15.42 | 469 / 504 |
ovary | 100% | 5506.47 | 180 / 180 | 90% | 9.87 | 385 / 430 |
liver | 100% | 2383.53 | 226 / 226 | 88% | 11.68 | 359 / 406 |
skin | 100% | 2372.68 | 1809 / 1809 | 87% | 18.31 | 412 / 472 |
pancreas | 82% | 622.69 | 269 / 328 | 98% | 23.15 | 175 / 178 |
kidney | 82% | 851.75 | 73 / 89 | 89% | 13.55 | 803 / 901 |
brain | 33% | 324.74 | 862 / 2642 | 75% | 10.85 | 527 / 705 |
adipose | 100% | 2166.85 | 1204 / 1204 | 0% | 0 | 0 / 0 |
blood vessel | 100% | 2916.19 | 1335 / 1335 | 0% | 0 | 0 / 0 |
spleen | 100% | 1934.35 | 241 / 241 | 0% | 0 | 0 / 0 |
heart | 99% | 3605.88 | 856 / 861 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 91% | 15.67 | 41 / 45 |
peripheral blood | 77% | 786.90 | 716 / 929 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 55% | 3.83 | 16 / 29 |
muscle | 25% | 158.35 | 203 / 803 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 16% | 0.97 | 13 / 80 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
GO_0030278 | Biological process | regulation of ossification |
GO_0048255 | Biological process | mRNA stabilization |
GO_0030501 | Biological process | positive regulation of bone mineralization |
GO_0045669 | Biological process | positive regulation of osteoblast differentiation |
GO_0009617 | Biological process | response to bacterium |
GO_0005737 | Cellular component | cytoplasm |
GO_0003723 | Molecular function | RNA binding |
GO_1990817 | Molecular function | poly(A) RNA polymerase activity |
GO_0005515 | Molecular function | protein binding |
Gene name | TENT5A |
Protein name | polynucleotide adenylyltransferase (EC 2.7.7.19) Alternative protein FAM46A Terminal nucleotidyltransferase 5A (EC 2.7.7.19) (HBV X-transactivated gene 11 protein) (HBV XAg-transactivated protein 11) |
Synonyms | XTP11 hCG_401094 FAM46A C6orf37 |
Description | FUNCTION: Cytoplasmic non-canonical poly(A) RNA polymerase that catalyzes the transfer of one adenosine molecule from an ATP to an mRNA poly(A) tail bearing a 3'-OH terminal group and participates in the cytoplasmic polyadenylation . Polyadenylates mRNA encoding extracellular matrix constituents and other genes crucial for bone mineralization and during osteoblast mineralization, mainly focuses on ER-targeted mRNAs (By similarity). . |
Accessions | H0Y5Y3 H0Y6D7 W5ZLG2 ENST00000369756.3 ENST00000369754.7 [Q96IP4-2] L8E8C7 Q96IP4 ENST00000423467.1 Q5TF85 ENST00000412306.1 W5ZL11 ENST00000320172.11 [Q96IP4-1] |